Zions Bancorporation, N.A. Bei Gene, Ltd. Transaction History

Zions Bancorporation, N.A.

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 05, 2022	SELL	$121.11 - $216.05 $1,332 - $2,376	-11 Closed	0 $0
Q1 2022 May 13, 2022	SELL	$146.52 - $269.56 $1,758 - $3,234	-12 Reduced 52.17%	11 $2,000
Q2 2021 Aug 11, 2021	SELL	$292.75 - $367.01 $1,756 - $2,202	-6 Reduced 20.69%	23 $8,000
Q4 2020 Feb 12, 2021	SELL	$221.31 - $316.61 $663 - $949	-3 Reduced 9.38%	29 $7,000
Q3 2020 Nov 13, 2020	BUY	$189.18 - $286.44 $567 - $859	3 Added 10.34%	32 $9,000

Q2 2020 Aug 13, 2020	BUY	$123.9 - $195.41 $3,221 - $5,080	26 Added 866.67%	29 $5,000
Q1 2020 May 15, 2020	BUY	$121.84 - $173.19 $365 - $519	3 New	3 $0
Q1 2019 May 10, 2019	SELL	$122.82 - $151.83 $2,947 - $3,643	-24 Closed	0 $0
Q4 2018 Feb 13, 2019	BUY	$107.01 - $175.15 $2,568 - $4,203	24 New	24 $3,000

216

45.1M

76.5K

72.3K

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $14.9B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

Get notified when there are updates to the investment portfolio of Zions Bancorporation, N.A., based on Form 13F filings with the SEC.

Stay updated on Zions Bancorporation, N.A. with notifications on news.